Evidence map›Paper›PMID 29755705›Full record

ReviewMediterranean journal of hematology and infectious diseases2018

Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients.

Rita Wilson Dib, Ray Hachem, Anne-Marie Chaftari, Issam Raad

Open access · goldAbstract readReview
In one paragraph

Review in Mediterranean journal of hematology and infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Biomarkers of fungal infection: Expert opinion on the current situation.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020
    Article
  4. Increase inMediterranean journal of hematology and infectious diseases · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Rita Wilson DibThe University of Texas M. D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, 1515 Holcombe, Unite 1460, Houston, Texas, 77030.
Ray HachemThe University of Texas M. D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, 1515 Holcombe, Unite 1460, Houston, Texas, 77030.
Anne-Marie ChaftariThe University of Texas M. D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, 1515 Holcombe, Unite 1460, Houston, Texas, 77030.
Issam RaadThe University of Texas M. D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health, 1515 Holcombe, Unite 1460, Houston, Texas, 77030.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this review, we have analyzed the available literature pertaining to the total duration of intravenous (IV) therapy and the appropriate timing of step down to oral therapy in the management of candidemia. Overview of the guidelines and literature seem to indicate that a minimum of 14 days of antifungal therapy is required in the treatment of candidemia without deeply seated infection. However, this was never based on evidence. Furthermore, step down to oral therapy seems to be dependent on the clinical stability criteria of the patient with candidemia after 4 to 7 days of IV therapy. Further studies are required to evaluate the appropriate total duration of IV therapy, appropriate timing of step down to oral therapy and to validate the clinical criteria that would allow the switch to happen.

Indexed as

CandidemiaIntravenous treatmentNon-nuetropenic patients

Identifiers

PMID29755705
PMCPMC5937951
OpenAlexW2801193635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.